Davin MARK BRowN MD FACS |4 #2 22* |
`
`dmbmd@retinaconsultantstexas.com
`www.retinaconsultantstexas.com
`Academic Administrator: Deneva Zamora
`Deneva_DB@retianconsultantstexas.com
`Phone: 713-394-7520
`
`Retina Consultants of Houston, PLLC d/b/a Retina Consultants of Texas
`Physician Partner & Director of Research
`1995-Present
`
`Newcastle Office (Main Office)
`4460 BissonnetStreet, Suite 200, Bellaire, Texas 77401
`
`The Woodlands Office
`17350 St. Luke’s Way, Suite 120, The Woodlands, Texas 77384
`
`Kingwood Office
`350 Kingwood Medical Drive, Suite 200, Kingwood, Texas 77339
`
`Space Center/Pasadena
`11460 Space Center Boulevard., Suite 2, Houston, TX 77059
`
`Katy Office
`23501 Cinco Ranch Boulevard, Suite G205, Katy, TX 77494
`
`Memorial Office
`
`902 Frostwood Drive, Suite 280, Houston, TX 77024
`
`Northwest Office
`21216 NW Freeway, Suite 630, Cypress, TX 77429
`
`Brenham TX Office
`2620 Hwy 36 South, Brenham, TX 77833
`
`Lufkin TX Office
`2906 BrentwoodDrive, Suite 300, Lufkin, TX 75901
`
`BOARDCERTIFICATION
`
`Diplomat, American Board of Ophthalmology 1994
`ABO Recertification (2005-2014) & (2015-2024)
`
`LICENSURE
`
`Texas License #H5425
`DEA#: BB1702213
`
`
`
`Mylan v. Regeneron
`IPR2021-00881
`U.S. Pat. 9,254 338
`Exhibit 2083
`
`Exhibit 2083
`Page 01 of 40
`
`Exhibit 2083
`Page 01 of 40
`
`

`

`EDUCATION & TRAINING
`
`1993-1995 University of lowa Hospitals & Clinics
`Medical Retina & Vitreoretinal Surgery Fellowship
`1990-1993 University of lowa Hospitals & Clinics
`Ophthalmology Residency
`1989-1990 Baylor College of Medicine
`Medical/Surgical Internship
`1984-1988 Baylor College of Medicine
`Doctorate of Medicine with “High Honors
`1981-1984 Houston Baptist University
`Bachelor of Science summa cum laude (4.0/4.0 GPA)
`
`ACADEMIC APPOINTMENTS
`
`Clinical Professor of Ophthalmology, Department of Ophthalmology
`Baylor College of Medicine, Houston, Texas
`
`Vice-Chair of Ophthalmology for Research, Department of Ophthalmology,
`The Methodist Hospital, Weill Cornell College of Medicine, Houston, Texas
`
`Associate Clinical Professor of Ophthalmology, The Methodist Hospital,
`Weill Cornell Medical College, Houston, Texas
`
`NASA- Research andClinical Advisory Panel-Space Associated Neuro-ophthalmic Syndrome
`NASAJohnson Space Center, Houston, Texas
`
`ACADEMIC & RESEARCH HONORS
`
`American Academy of Ophthalmology Senior Achievement Award 2014
`American Society of Retina Specialists (ASRS) Senior Honor Award 2010
`American Society of Retina Specialists (ASRS) Honor Award 2008
`Academy of Ophthalmology Honor Award 2000
`Heed-Knapp Ophthalmic Foundation Fellowship 1994-1995
`Ronald G. Michels Foundation Fellowship Award 1994
`(presented to most outstanding U.S. Retina fellow)
`Heed Ophthalmic Foundation Thomas Heed Fellowship 1993-1994
`PJ Leinfelder Award (most outstanding research in residency) 1991-1992
`
`ELECTED HONORARYSOCIETIES & LISTS
`
`Club Jules Gonin Society (2018)
`RETINA HALL OF FAME (charter inductee- 2017)
`Texas Monthly “Super Doc” (2009-2019)
`“Best Doctors In America” (2007-2019)
`Macula Society (2008-present)
`Retina Society (2006-present)
`Ronald G. Michels Fellowship Society (1994)
`Society of Thomas Heed Fellows (1993)
`Alpha Omega Alpha Medical HonorSociety (1985)
`
`Exhibit 2083
`Page 02 of 40
`
`David M. Brown MD FACS
`Page 2
`
`Exhibit 2083
`Page 02 of 40
`
`

`

`PROFESSIONAL ORGANIZATIONS & SOCIETIES
`
`Fellow, American Academy of Ophthalmology
`Diplomate, American Board of Ophthalmology
`Harris County OphthalmologySociety
`Harris County Medical Society
`lowa Eye Association
`Fellow, American College of Surgeons
`Association for Research in Vision (ARVO}
`American Society of Retina Specialists
`American Society of Cataract & Refractive Surgery
`American Diabetes Association
`Juvenile Diabetes Research Foundation
`Texas Ophthalmologic Association
`American Medical Association
`
`PROFESSIONAL ORGANIZATIONS & SOCIETIES-LEADERSHIP ROLES
`
`American Society of Retina Specialists - Board of Directors 2014-present
`American Society of Retina Specialists - Practice Management Chair 2014-17
`AmericanSociety of Retina Specialists - Governmental Affairs 2017-present
`The Foundation of the ASRS- Board of Directors 2014-present
`Macula Society - Credentials Committee 2013-present
`Retina Society- Finance Committee- 2018-present
`Retina Society - Nominating Committee Chairman 2013-15
`Retina Society - Nominating Committee 2011-15
`American Society of Cataract & Refractive Surgery- Retina Clinical Committee 2015-present
`Methodist ResearchInstitute - Internal Advisory Committee 2004-2012
`Diabetic Retinopathy Clinical Research Network - Executive Committee 2005-2007
`Diabetic Research Clinical Network (DRCR) - Planning Committee 2004-2005
`Methodist Hospital! Research Institute SPRINT - Planning Committee 2003-2004
`Harris County Ophthalmology Society - President 2002-2003
`Harris County Ophthalmology Society - Executive Committee 1997-2003
`lowa Eye Association - President 2002-2003
`University of lowa Center for Macular Degeneration - Advisory Board 2003-present
`Juvenile Diabetes Research Foundation - Board of Directors 1998-2002
`Houston American Diabetes Association - Medical Advisory Board 2000-2002
`Houston Area American Diabetes Association - Board of Directors 1998-2001
`
`PEER REVIEWER
`
`American Journal of Ophthalmology
`Archives of Ophthalmology
`British Journal of Ophthalmology
`EYE
`
`New England Journal of Medicine
`OPHTHALMOLOGY
`
`RETINA, The Journal of Retina & Vitreous Diseases
`RETINA, Cases & Brief Reports
`
`Exhibit 2083
`Page 03 of 40
`
`David M. Brown MD FACS
`Page 3
`
`Exhibit 2083
`Page 03 of 40
`
`

`

`GOOGLE SCHOLAR/ EXPERTSCAPE RANKINGS
`h-Index: 45
`i10 Index: 74
`Citations: 21,892
`
`Expertscape rankings: -based on Pubmed publications past 10 years (www.expertscape.com)
`Retinal Vein Occlusion: #3 worldwide, #1 Texas
`Macular Degeneration: #13 worldwide, #5 US, #1 Texas
`Diabetic Retinopathy: Top 30 Worldwide, #1 Texas
`
`Pub-Med Indexed ORIGINAL PAPERS- Author
`
`- Abraham JR, Wykoff CC, Arepalli S, Lunasco L, Yu HJ, Hu M, Reese J, Srivastava SK, Brown DM,Ehlers JP. Aqueous Cytokine
`Expression and Higher Order OCT Biomarkers: Assessment of the Anatomic-Biologic Bridge in the IMAGINE DME Study. Am
`J Ophthalmol. 2020 Sep 5;222:328-339. PMID: 32896498.
`
`-Fan W, Uji A, Wang K, Falavarjani KG, Wykoff CC, Brown DM, Van HemertJ, Sagong M, Sadda SR,Ip M. Severity of Diabetic
`Macular Edema Correlates with Retinal Vascular Bed Area on Ultra-Wide Field Fluorescein Angiography: DAVE Study.
`Retina. 2020 Jun;40(6):1029-1037 PMID: 31356494.
`
`-Yu HJ, Kaiser PK, Zamora D, Bocanegra M, Cone C, Brown DM,Sadda SR, Wykoff CC. Visual Acuity Variability: Comparing
`Discrepancies between Snellen and ETDRS Measurements amongSubjects Entering Prospective Trials. OphthalmolRetina.
`2020 Apr 23:$2468-6530(20)30154-8. PMID: 32595096.
`
`-Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM; TREX-DME Study Group. Long-term outcomesof treat-and-
`extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results. BrJ
`Ophthalmol. 2020 Apr 17:bjophthalmol-2020-316176. PMID: 32303499.
`
`-MajorJC Jr, Lampen SIR, Wykoff CC, Ou WC, Brown DM, WongTP, Shah AR. The Texas Taco Technique For Internal Limiting
`
`MembraneFlap In Large Full-Thickness Macular Holes: A Short-Term Pilot Study. Retina. 2020 Mar;40(3):552 556. PMID:
`30608347.
`
`-Zhou B, Mitchell TC, Rusakevich AM, Brown DM, Wykoff CC. Noncompliance in Prospective Retina Clinical Trials: Analysis
`of Factors Predicting Loss to Follow-up. Am J Ophthalmol. 2020 Feb;210:86-96. Epub 2019 Oct 21. PMID: 31647931.
`
`-Heier JS, Wykoff CC, Waheed NK, Kitchens JW,Patel SS, Vitti R, Perlee L, Chu KW,Leal S, Asmus F, Son V, SchmelterT,
`Brown DM. Intravitreal CombinedAflibercept + Anti-Platelet-Derived Growth Factor Receptor B for Neovascular Age-
`Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial. Ophthalmology. 2020 Feb;127(2):211-220. Epub 2019
`Sep 25. PMID: 31791663.
`
`-Liao DS, Grossi FV, El Mehdi D, Gerber MR, Brown DM,Heier JS, Wykoff CC, Singerman LJ, Abraham P, Grassmann F,
`Nuernberg P, Weber BHF, Deschatelets P, Kim RY, Chung CY, Ribeiro RM, HamdaniM, Rosenfeld PJ, BoyerDS, SlakterJS,
`Francois CG. ComplementC3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular
`Degeneration: A Randomized Phase2 Trial. Ophthalmology. 2020 Feb;127(2):186-195. Epub 2019 Jul 16. PMID: 31474439.
`
`-Fan W, Nittala MG, Fleming A, Robertson G, Uji A, Wykoff CC, Brown DM,van Hemert J, Ip M, WangK, Falavarjani KG,
`Singer M, Sagong M,SaddaSR. Relationship Between Retinal Fractal Dimension and Nonperfusionin Diabetic Retinopathy
`on Ultrawide-Field Fluorescein Angiography. Am J Ophthalmol. 2020 Jan;209:99-106. Epub 2019 Aug 29. PMID: 31472160.
`
`-Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, Gomes AV, Warburton J, Weichselberger A, Holz FG;
`HAWKand HARRIER StudyInvestigators. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double MaskedTrials of
`Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020 Jan;127(1):72-84. Epub 2019 Apr
`12. PMID: 30986442.
`
`Exhibit 2083
`Page 04 of 40
`
`David M. Brown MD FACS
`Page 4
`
`Exhibit 2083
`Page 04 of 40
`
`

`

`-Wykoff CC, Nittala MG, Zhou B, Fan W, Velaga SB, LampenSIR, Rusakevich AM, Ehlers JP, Babiuch A, Brown DM,Ip MS,
`SaddaSR;Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy Study Group.
`Intravitreal Aflibercept for Retinal Nonperfusionin Proliferative Diabetic Retinopathy: Outcomes from the Randomized
`RECOVERYTrial. Ophthalmol Retina. 2019 Dec;3(12):1076-1086. Epub 2019 Jul 24. PMID: 31542339.
`
`-Ehlers JP, Uchida A, Hu M, Figueiredo N, Kaiser PK, Heier JS, Brown DM, Boyer DS, Do DV, GibsonA, Saroj N, Srivastava SK.
`Higher-Order Assessment of OCT in Diabetic Macular Edema from the VISTA Study: Ellipsoid Zone Dynamics and the Retinal
`Fluid Index. Ophthalmol Retina. 2019 Dec;3(12):1056-1066. Epub 2019 Jul 6. PMID: 31473172.
`
`-Fang M,Fan W,Shi Y, lp MS, Wykoff CC, Wang K, Falavarjani KG, Brown DM, van HemertJ, Sadda SR.Classification of
`Regions of Nonperfusion on Ultra- widefield Fluorescein Angiography in Patients with Diabetic Macular Edema. Am J
`Ophthalmol. 2019 Oct;206:74-81. Epub 2019 Apr 6. PMID: 30959003.
`
`-Feltgen N, Ogura Y, Boscia F, Holz FG, Korobelnik JF, Brown DM, Heier JS, Stemper B, Rittenhouse KD, AsmusF, Ahlers C,
`Vitti R, Saroj N, Mitchell P. Impact of Baseline Retinal Nonperfusion and Macular Retinal Capillary Nonperfusion on
`Outcomesin the COPERNICUS and GALILEO Studies. Ophthalmol Retina. 2019 Jul;3(7):553-560. Epub 2019 Feb 27, PMID:
`31277796.
`
`-Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM; TREX-DME Study Group. RandomizedTrial of Treat and
`Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-
`Year Outcomes. Am J Ophthalmol. 2019 Jun;202:91-99. Epub 2019 Feb 14. PMID: 30771333.
`
`-Kim RS, Jain RR, Brown DM, Bretana ME, Kegley EN, Singer MA, Aragon AV, Schefler AC. Elevated Choroidal Thickness and
`Central Serous Chorioretinopathy in the Fellow Eyes of Patients with Circumscribed Choroidal Hemangioma. Ocul Oncol
`Pathol. 2018 Nov;4(6):375-380. Epub 2018 Apr 20. PMID: 30574490.
`
`-Mitchell P, McAllister |, Larsen M, Staurenghi G, Korobelnik JF, Boyer DS, Do DV, Brown DM,Katz TA, Berliner A,Vitti R,
`Zeitz O, Metzig C, Lu C, Holz FG. Evaluating the Impactof Intravitreal Aflibercept on Diabetic Retinopathy Progression in the
`VIVID-DME and VISTA-DME Studies. Ophthalmol Retina. 2018 Oct;2(10):988-996. Epub 2018 Mar 31. PMID: 31047501.
`
`-Lampen SIR, Khurana RN, Noronha G, Brown DM, Wykoff CC. Suprachoroidal Space Alterations Following Delivery of
`Triamcinolone Acetonide: Post-Hoc Analysis of the Phase 1/2 HULK Study of Patients With Diabetic Macular Edema.
`
`Ophthalmic Surg Lasers Imaging Retina. 2018 Sep 1;49(9):692-697. PMID: 30222804.
`
`-Wykoff CC, Khurana RN, Lampen SIR, Noronha G, Brown DM, Ou WC, Sadda SR; HULK Study Group. Suprachoroidal
`Triamcinolone Acetonide for Diabetic Macular Edema: The HULK Trial. Ophthalmol Retina. 2018 Aug;2(8):874-877. Epub
`2018 May 4. PMID: 31047542.
`
`-Kwon S, Wykoff CC, Brown DM, van Hemert J, Fan W, Sadda SR. Changesin retinal ischaemic index correlate with
`recalcitrant macular oedemain retinal vein occlusion: WAVE study. Br J Ophthalmol. 2018 Aug;102(8):1066-1071. Epub
`2018 Apr 26. PMID:29699979.
`
`-Brown DM, Ou WC, WongTP, Kim RY, Croft DE, Wykoff CC; DAVE Study Group. Targeted Retinal Photocoagulation for
`Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVETrial. Ophthalmology. 2018
`May;125(5):683-690. PMID: 29336896.
`
`-Payne JF, Clark WL, Bruce BB, Wykoff CC, Brown DM, Menke BM,Iverson SM,Allen KF, Boyer DS; Treat & Extend Protocol
`in Patients with Diabetic Macular Edema Study Group. Retinopathy Regression with Treat and Extend Ranibizumab for
`Diabetic Macular Edema. Ophthalmology. 2018 May 2. pii: $0161-6420(18)30678-xX.PubMed PMID: 29729809.
`
`Exhibit 2083
`
`Page 05 of 40
`
`David M. Brown MD FACS
`
`Page 5
`
`Exhibit 2083
`Page 05 of 40
`
`

`

`-Brown DM, Ou WC, Wong TP, Kim RY, Croft DE, Wykoff CC; DAVE Study Group. Targeted Retinal Photocoagulation for
`Diabetic Macular Edemawith Peripheral Retinal Nonperfusion: Three-Year Randomized DAVETrial. Ophthalmology. 2018
`May;125(5):683-690.PubMed PMID: 29336896.
`
`-Wykoff CC, Ou WC, Khurana RN, Brown DM,Lloyd Clark W, Boyer DS; ENDURANCEStudy Group. Long-term outcomes with
`as-neededafliberceptin diabetic macular edema: 2-year outcomesof the ENDURANCEextension study. Br J Ophthalmol.
`2018 May;102(5):631-636. PubMed PMID: 28814412.
`
`-Campochiaro PA, Wykoff CC, Brown DM, Boyer DS, Barakat M, Taraborelli D, Noronha G; Tanzanite Study Group.
`Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study. OphthalmolRetina. 2018
`Apr;2(4):320-328. PMID: 31047241.
`
`-Brown DM,HeierJS, Boyer DS, Freund KB, KaiserP, Kim JE, Sarraf D.- Current Best Clinical Practices—Management of
`Neovascular AMD J. VitreoRetinal Diseases. 2017 1(5) 294-297.
`
`-Kwon S, Wykoff CC, Brown DM,van HemertJ, Fan W, Sadda SR. Changesin retinal ischaemic index correlate with
`recalcitrant macular oedemain retinal vein occlusion: WAVE study. Br J Ophthalmol. 2018 Apr 26. pii: bjophthalmol-2017-
`311475.PubMed PMID: 29699979.
`
`-Wykoff CC, Ou WC, Croft DE, Payne JF, Brown DM,Clark WL, Abdelfattah NS, Sadda SR; TREX-AMD Study Group.
`Neovascular age-related macular degeneration managementin thethird year:final results from the TREX-AMD randomised
`trial. Br J Ophthalmol. 2018 Apr;102(4):460-464. PubMed PMID: 28779006.
`
`
`-Brown DM, Wykoff CC.Intravitreal aflibercept for proliferative diabetic retinopathy. Lancet. 2017 Nov
`11;390(10108):2141. PubMed PMID: 29143753.
`
`-Fan W, WangK, Ghasemi Falavarjani K, Sagong M,Uji A, lp M, Wykoff CC, Brown DM,van HemertJ, SaddaSR. Distribution
`of Nonperfusion Area on Ultra-widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE Study. Am J
`Ophthalmol. 2017 Aug;180:110-116. PubMed PMID: 28579062.
`
`-Jackson TL, Boyer DS, Brown DM,Chaudhry N, Elman M,Liang C, O’Shaughnessy D,ParsonsE, Patel S, Slakter JS, Rosenfeld
`PJ. Oral tyrosine kinase inhibitor for neovascular age-related macular degeneration: a phase 1 DoseEscalation Study. JAMA
`Opthalmology- 2017 Jul 1;135(7):761-767. PubMed PMID: 28570723.
`
`-Wykoff CC, Ou WC, Wang R, Brown DM,ConeC, Zamora D, Le RT, Sagong M, Wang K, Sadda SR; WAVE Study Group..
`Peripheral Laser for Recalcitrant Macular Edema Owingto Retinal Vein Occlusion: The WAVETrial. Ophthalmology. 2017
`Jun;124(6):919-921. PMID: 28318636.
`
`-Ou WC, Brown DM,Payne JF, Wykoff CC. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular
`Endothelial Growth Factor Therapy for Retinal Diseases. Am J Ophthalmol. 2017 May23. pii: S0002-9394(17)30216-7. PMID:
`28549848.
`
`-Wykoff CC, Le RT, Khurana RN, Brown DM, Ou WC, WangR,Clark WL, Boyer DS; ENDURANCEStudy Group. Reply. Am J
`Ophthalmol. 2017 May;177:236-237. PubMed PMID: 28302270.
`
`-Ho AC, Albini TA, Brown DM, Boyer DS,Regillo CD, Heier JS. The Potential Importance of Detection of Neovascular Age-
`Related Macular Degeneration WhenVisual Acuity Is Relatively Good. JAMA Ophthalmol. 2017 Mar 1;135(3):268-273. PMID:
`28114653.
`
`- Wykoff CC, Le RT, Khurana RN, Brown DM, Ou WC, WangR, Clark WL, Boyer DS; ENDURANCE Study Group.. Outcomes With
`As-Needed Aflibercept and Macular Laser Following the PhaseIII VISTA DME Trial: ENDURANCE 12-Month Extension Study.
`Am J Ophthalmol. 2017 Jan;173:56-63. PMID: 27702624.
`
`-Payne JF, Wykoff CC, Clark WL, Bruce 88, Boyer DS, Brown DM; TREX-DME Study Group.. RandomizedTrial of Treat and
`
`David M. Brown MD FACS
`Page 6
`
`Exhibit 2083
`
`Page 06of 40
`
`Exhibit 2083
`Page 06 of 40
`
`

`

`Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes.
`Ophthalmology. 2017 Jan;124(1):74-81. PMID: 27836430.
`
`-Wang R, Wykoff CC, Brown DM. Granular Hyper-reflective Specks by Spectral Domain Optical Coherence Tomographyas a
`sign of WestNile Virus infection: The Stardust Sign Retin Cases Brief Rep. 2016 Fall;10(4):349-53. PMID: 26674277.
`
`-Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, BoyerDS, Terasaki H, Kaiser PK, Marcus DM, Nguyen
`QD,Jaffe GJ, Slakter JS, Simader C, Soo Y, SchmelterT,Vitti R, Berliner AJ, Zeitz O, Metzig C, Holz FG. Intravitreal Aflibercept
`for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. Ophthalmology. 2016 Nov;123(11):2376-
`2385. PMID: 27651226.
`
`-Clark WL, BoyerDS, Heier JS, Brown DM,Haller JA, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW,SooY, ChengY,
`Campochiaro PA.Reply. Ophthalmology. 2016 Oct;123(10):e60-1. PubMed PMID: 27664917.
`
`- Wang R, Wykoff CC, Christie L, Croft DE, Major JC Jr, Fish RH, Brown DM.Choroidal Neovascularization Secondary to
`Alexandrite Laser Exposure. Retina Cases Brief Rep. 2016 Summer;10(3):244-8. PMID: 26584328.
`
`-Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, ChengY,
`Campochiaro PA.Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the
`VIBRANTStudy. Ophthalmology. 2016 Feb;123(2):330-6. Epub 2015 Oct 30. PMID: 26522708.
`
`-Heier JS, Bressler NM, Avery RL, Bakri SJ, Boyer DS, Brown DM, Dugel PU, Freund KB, Glassman AR, Kim JE, Martin DF, Pollack
`JS, Regillo CD, Rosenfeld PJ, Schachat AP, Wells JA 3rd; American Society of Retina Specialists Anti-VEGF for Diabetic Macular
`Edema Comparative Effectiveness Panel. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of
`Diabetic Macular Edema: Extrapolation of Data to Clinical Practice. JAMA Ophthalmol. 2016 Jan 1;134(1):95-9. PMID:
`26512939.
`
`-WangR, Wykoff CC, Brown DM. Granular Hyperreflective Specks by Spectral Domain Optical Coherence Tomographyas Signs
`of West Nile Virus Infection: The Stardust Sign. Retina Cases Brief Rep. 2015 Dec 13. PMID: 26674277.
`
`-Li AL, Wykoff CC, Wang R, Chen E, Benz MS, Fish RH, Wong TP, Major JC Jr, Brown DM, Schefler AC, Kim RY, O’Malley RE.
`
`Endophthalmitis after Intravitreal injection-: Role of Prophylactic Topical Ophthalmic Antibiotics. Retina. 2015 Dec 11. PMID:
`26655622.
`
`-Major JC Jr, Wykoff CC, Croft DE, Wang R, Mariani AF, Lehmann AE, Brown DM. Aflibercept for pigment epithelial detachment
`for previously treated neovascular age-related macular degeneration. Can J Ophthalmol. 2015 Oct;50(5):373-7. Epub 2015
`Aug 12. PMID: 26455973.
`
`-Boyer DS, Nguyen QD, Brown DM,Basu K, Ehrlich JS; RIDE and RISE Research Group. Outcomeswith As-Needed Ranibizumab
`after Initial Monthly Therapy: Long-Term Outcomes of the Phase Ill RIDE and RISE Trials. Ophthalmology. 2015
`Dec;122(12):2504-2513. Epub 2015 Oct 9. PMID: 26452713.
`
`
`-Brown DM, Wykoff CC, Croft DE, Wong TP; RAVE Study Group. Reply: To PMID 24914476. Retina. 2015 Oct;35(10):e61-3
`PMID: 26398558.
`
`-Wykoff CC, Croft DE, Brown DM, Wang R, PayneJF, Clark L, Abdelfattah NS, Sadda SR; TREX-AMD Study Group. Prospective
`Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year
`Results. Ophthalmology. 2015 Dec;122(12):2514-22. Epub 2015 Sep 29, PMID: 26391465.
`
`-Brown DM,Schmidt-Erfurth U, Do DV, Holz FG, Boyer DS, MidenaE, Heier JS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD,
`Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Korobelnik
`JF. Intravitreal Aflibercept for Diabetic Macular Edema: 100-WeekResults From the VISTA and VIVID Studies. Ophthalmology.
`2015 Oct;122(10):2044-52. Epub 2015 Jul 18. PMID: 26198808.
`
`-Croft DE, Wykoff CC, van Hemert J, Verhoek M, Brown DM. NotAll Retina Is Created Equal: Metabolic Quantification of Ultra-
`Widefield Images. Ophthalmology. 2015 Dec;122(12):2580-2. Epub 2015 Jun 26. PMID: 26123089.
`
`David M. Brown MD FACS
`
`Page 7
`
`Exhibit 2083
`
`Page 07 of 40
`
`Exhibit 2083
`Page 07 of 40
`
`

`

`-Brown DM, Korobelnik JF; VISTA and VIVID study investigators. Intravitreal aflibercept for diabetic macular edema.
`Ophthalmology. 2015 Jun;122(6):e38-9. PMID: 26008916.
`
`-Wykoff CC, Brown DM,Croft DE, Major JC Jr, Wong TP. Progressive Non-Perfusionin Ischemic Central Retinal Vein Occlusion.
`RETINA. 2015 Jan; 35(1): 43-7. PMID: 25102193.
`
`-CampochiaroPA, Clark WL, BoyerDS, Heier JS, Brown DM,Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW,Soo Y, ChengY,
`Haller JA. Intravitreal Aflibercept for Macular EdemaFollowing Branch Retinal Vein Occlusion: The 24-Week Results of the
`VIBRANT Study. Ophthalmology. 2015 Mar;122(3):538-44. PMID: 25315663.
`
`-Brown DM. Eight Questions with Dr. Puliafito. Ophthalmic Surg Lasers Imaging Retina. 2014 Jul 1;45(4):353-5. PMID:
`25037016.
`
`- Croft DE, van HemertJ, Wykoff CC,Clifton D, Verhoek M, Fleming A, Brown DM. Precise montaging and metric quantification
`of retinal surface area from ultra-widefield fundus photography and fluorescein angiography. Ophthalmic Surg Lasers
`Imaging Retina. 2014 Jul-Aug 1;45(4):312-7. PMID: 25037013.
`
`-Korobelnik J-F, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FJ, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM, Nguyen
`NJ, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl NS, Vitti R, Berliner AJ, Zeitz O, Metzig C, Brown
`DM. Intravitreal Aflibercept for Diabetic Macula Edema. Ophthalmology. 2014 Nov. 121(11):2247-54. Epub 2014 Jul 8. PMID:
`25012934..
`
`- Brown DM, Wykoff CC, Wong TP, Mariani AF, Croft DE, Schuetzle K for the RAVE STUDY GROUP,Ranibizumab in Pre-
`Proliferative (Ischemic) Central Retinal Vein Occlusion (CRVO): The Rubeosis Anti- VEgf (RAVE) Trial. RETINA. 2014.
`Sep;34(9):1728-35 PMID: 24914476.
`
`- Heier JS, Clark WL, Boyer DS, Brown DM,Vitti R, Berliner AJ, Kazmi H, Ma Y, StemperB, Zeitz O, Sandbrink R, Haller JA.
`Intravitreal aflibercept
`injection for macular edema due to central retinal vein occlusion: two-year results from the
`COPERNICUSstudy. Ophthalmology. 2014 Jul;121(7):1414-1420. Epub 2014 Mar 27. PMID: 24679444,
`
`-Karth PA, Raja SC, Brown DM,Kim JE. Outcomes of Macular Hole Surgeries for Macular Telangiectasia Type 2. RETINA. 2014
`May;34(5):907-15. PMID: 24270919.
`
`- Wykoff CC, Brown DM, Maldonado ME, Croft DE. Aflibercept treatment for patients with exudative age-related macular
`degeneration who were incomplete responders to multiple ranibizumab injections (TURFtrial). Br J Ophthalmol. 2014
`Jul;98(7):951-5. Epub 2014 Feb 11. PMID: 24518078.
`
`- Takakura A, Tessler HH, Goldstein DA, Guex-Crosier Y, Chan CC, Brown DM,Thorne JE, Wang R, Cunningham ETJr. Viral
`retinitis following intraocular or periocular corticosteroid administration: a case series and comprehensive review of the
`literature. Ocul ImmunolInflamm. 2014 Jun;22(3):175-82. PMID: 24655372.
`
`-Campochiaro PA, Sophie R, Pearlman J, Brown DM, BoyerDS, Heier JS, Marcus DM,FeinerL, Patel A; RETAIN Study Group.
`Long-term outcomesin patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology.
`2014 Jan;121(1):209-19. PMID: 24112944.
`
`-Heier JS, Brown DM,ChongV, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, OguraY, Schmidt-Erfurth U. Author
`reply: To PMID 23084240. Ophthalmology. 2014 Jan;121(1):e5-e6. PMID: 24536092.
`
`-Major JC, Wykoff CC, Mariani AF, Chen E, Croft DE, Brown DM. Comparison of spectral-domain and time-domain optical
`
`coherence tomography in the detection of neovascular age related macular degeneration activity. RETINA.
`2014
`Jan;34(1):48-54. PMID: 23764967.
`
`-Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, SimaderC,Jaffe GJ, Slakter
`JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, SowadeO,Zeitz O, Norenberg C, Sandbrink R, HeierJS.
`Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results of the VIEW
`Studies. Ophthalmology. 2014 Jan;121(1):193-201. Epub 2013 Sep 29. PMID: 24084500.
`
`David M. Brown MD FACS
`Page 8
`
`Exhibit 2083
`
`Page 08of 40
`
`Exhibit 2083
`Page 08 of 40
`
`

`

`-Wykoff CC, Brown DM, Croft DE, Wong TP. Two year SAVE (Super-dose anti-VEGF) outcomes: 2.0 mg ranibizumab for
`recalcitrant neovascular age-related macular degeneration. Ophthalmology. 2013 Sep;120(9):1945-1946. PMID: 24001533.
`
`- Mariani AF, Major JC Jr, Brown DM, Wykoff CC, Benz MS, Kegley EN. Purtscher-like retinopathy associated with pemphigus
`vulgaris. Retin Cases Brief Rep. 2013 Fall;7(4):304-6. PMID: 25383823.
`
`-Busbee BG, Ho AC, Brown DM, HeierJS, Sufier U, Li Z, Rubio RG, Lai P; HARBOR Study Group. Twelve-month efficacy and
`safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
`Ophthalmology. 2013 May;120(5):1046-56. PMID: 23352196.
`
`-Campochiaro PA, ChannaR, Berger BB, Heier JS, Brown DM,Fiedler U, Hepp J, Stumpp MT. Treatment of diabetic macular
`edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase 1/Il study. American
`Journal Ophthalmology. 2013 Apr;155(4):697-704. PMID: 23218689.
`
`-Brown DM, ChenE, Mariani A, Major JC Jr; SAVE Study Group; Super-dose Anti-VEGF (SAVE) Trial: 2.0 mg Intravitreal
`Ranibizumab for Recalcitrant Neovascular Macular Degeneration-Primary End Point. Ophthalmology. 2013 Feb;120(2):349-
`54. PMID: 23131717.
`
`-Wykoff CC, Brown DM, Chen E, Major JC, Croft DE, Mariani A, Wong TP. SAVE (Super-dose anti-VEGF) trial: 2.0 mg
`ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. Ophthalmic Surg Lasers Imaging
`Retina. 2013; 44(2):121-6. PMID: 23510037.
`
`-Brown DM, Nguyen QD, Marcus DM,BoyerDS,Patel S, Feiner L, Schlottmann PG, Rundle AC, Zhang J, Rubio RG, Adamis AP,
`Ehrlich JS, Hopkins Jj; RIDE and RISE Research Group. Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular
`Edema: The 36-MonthResults from Two Phase III Trials: RISE and RIDE. Ophthalmology. 2013 Oct; 120(10):2013-2022. PMID:
`23706949.
`
`Intravitreal aflibercept
`-Brown DM,Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O, Sandbrink R, Zhu X, Haller JA.
`injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUSstudy.
`American Journal Ophthalmology. 2013 Mar;155(3):429-437. PMID: 23218699.
`
`-Campochiaro PA, Nguyen QD,Hafiz G, Bloom S, Brown DM, Busquets M,Ciulla T, Feiner L, Sabates N,Billman K, Kapik B,
`Green K, Kane FE, FAMOUS Study Group. Aqueous levels of fluocinolone acetonide after administration of fluocinolone
`acetonideinserts or fluocinolone acetonide implants. Ophthalmology. 2013 Mar;120(3):583-7. PMID: 23218184.
`
`-Brown DM, Nguyen QD,Ehrlich JS; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema. Authorreply.
`Ophthalmology. 2013 Jan;120(1):221-2. PMID: 23283201.
`
`-Brown DM, Tuomi L, Shapiro H; For The Pier Study Group . Anatomical Measures as predictors of visual outcomes in
`
`ranibizumab-treated eyes with Neovascular Age-Related Macular Degeneration. RETINA. 2013 Jan;33(1):23-34. PMID:
`23073338.
`
`-Heier JS, Brown DM, ChongV, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD,Stahl N,Vitti
`R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW
`2 Study Groups.Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-Related Macular Degeneration. Ophthalmology. 2012
`Dec;119(12):2537-48. PMID: 23084240.
`
`-Campochiaro PA, Brown DM,Pearson A, Chen S, Boyer D, Ruiz-Moreno J, Garretson B, Gupta A, Hariprasad SM,Bailey C,
`Reichel E, SoubraneG, Kapik B, Billman K, Kane FE, Green K; FAME Study Group. Sustained delivery fluocinolone acetonide
`vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012 Oct;
`119(10):2125-32. PMID: 22727177.
`
`-Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM,Vitti R, Berliner AJ, Gao B, Zeitz O, Ruckert R, Schmelter T,
`Sandbrink R, Heier JS; DA VINCI Study Group. One-year outcomesof the DA VINCI Study of VEGF Trap-Eyein eyes with diabetic
`macular edema. Ophthalmology. 2012 Aug;119(8):1658-65. PMID: 22537617.
`
`David M. Brown MD FACS
`
`Page 9
`
`Exhibit 2083
`
`Page 09 of 40
`
`Exhibit 2083
`Page 09 of 40
`
`

`

`-Boyer D, Heier J, Brown DM,Clark WL, Vitti R, Berliner AJ, GroetzbachG,Zeitz O, Sandbrink R, Zhu X, Beckmann K, Haller JA.
`Vascular endothelial growth factor Trap-Eye for macular edema secondaryto central retinal vein occlusion: six-monthresults
`of the phase 3 COPERNICUS study. Ophthalmology. 2012 May;119(5):1024-32. PMID: 22440275.
`
`-Nguyen QD, Brown DM*, Marcus DM,BoyerDS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS;
`RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phaseIII randomizedtrials: RISE and
`RIDE. Ophthalmology. 2012 Apr;119(4):789-801.*Co-First Author PMID: 22330964,
`
`-Chen E, Lin MY, Cox J, Brown DM. Endophthalmitis after intravitreal injection: the importance of Viridans Streptococci.
`
`RETINA. 2011 Sep; 31(8) 1525-33. PMID: 21878800.
`
`-~Campochiaro PA, Brown DM, AwhCC,Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG. Sustained benefits of ranibizumab
`for macular edema following central retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011
`Oct; 118:(10) 2041-49. PMID: 21715011.
`
`-Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY. Sustained benefits
`of ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phaseIll study.
`Ophthalmology. 2011 Aug;118(8):1594-602 PMID: 21684606.
`
`-Zhang K, Hopkins JJ, Heier JS, Birch DG, Halperin LS, Albini TA, Brown DM,Jaffe GJ, Tao W, Williams GA. Ciliary neurotrophic
`factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular
`degeneration. Proc Natl Acad Sci USA. 2011 Apr 12; 108(15) 6241-5. PMID: 21444807.
`
`-Heier JS, Boyer D, Nguyen QD, Marcus D, Roth DB, YancopoulosG, Stahl N, Ingerman A,Vitti R, Berliner AJ, Yang K, Brown
`DMfor the CLEAR-IT 2 Investigators 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth FactorTrap-
`Eye Dosed As-needed After 12-week Fixed Dosing. Ophthalmology. 2011 Jun; 118(6) 1098-1106. PMID: 21640258.
`
`-Brown DM,JS Heier, Ciulla T, Ben M, Abraham P, Yancopoulos G, Stahl N, Ingerman A,Vitti R, Berliner AJ, Yang K, Nguyen
`QD, CLEAR-IT 2 Investigators. Primary Endpoint Results of a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye in
`Wet Age-Related Macular Degeneration. Ophthalmology. 2011 Jun; 118(6) 1089-97. PMID: 21640257.
`
`-Campochiaro PA, Brown DM,Pearson A, Ciulla T, Boyer D, Holz FG, Tolentino M, Gupta A, Duarte L, Madreperia S, GonderJ,
`Kapik B, Billman K, Kane FE, FAME STUDY GROUP. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous
`inserts for diabetic macular edema. Ophthalmology. 2011 Apr; 118(6) 626-35. PMID: 21459216.
`
`- Heier JS, Brown DM, Ciulla T, Abraham P, Bankert JM, Chong S, Daniel PE Jr, Kim IK. Ranibizumab for choroidal
`neovascularization secondaryto causesother than age-related macular degeneration: a phase| clinical trial. Ophthalmology.
`2011 Jan; 118(1) 111-8. PMID: 20678799.
`
`- Chen E, Brown DM, WongTP, Benz MS, Kegley E, Cox J, Fish RH, Kim RY. Lucentis using Visudyne study: determining the
`threshold-dose fluence of Verteporfin photodynamic therapy combinedwithintravitreal ranibizumab for exudative macular
`degeneration. Clin Ophthalmol. 2010 Oct 5; 5(4) 1073-9. PMID: 20957143.
`
`-Chen E, Brown DM,Benz MS, Fish RH, Wong TP, Kim RY, Major JC. Spectral domain optical coherence tomography as an
`effective screening test for hydroxychloroquine retinopathy (the "flying saucer"sign). Clin Ophthalmol. 2010 Oct 21; 4: 1151-
`8. PMID: 21060664.
`
`- Campochiaro PA, Hafiz G,